Inflammatory Pathways in Coronary Artery Disease: Which Ones to Target for Secondary Prevention?
Cells · 2025
DOI: 10.3390/cells14030153 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Wan-Hei Cheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada. Hauptthemen laut MEDLINE: Coronary Artery Disease, Inflammation, Secondary Prevention. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heart and Stroke Foundation of Canada, Mitacs Accelerate Award, Michael Smith Health Research British Columbia.
Abstract (Originalsprache)
Coronary artery disease (CAD), the build-up of atherosclerotic plaques on the wall of blood vessels, causes adverse cardiovascular events. Secondary prevention focuses on treating patients with existing plaques to prevent disease progression. Recent studies have shown that inflammation is an independent risk factor that drives disease progression, and targeting inflammation could be an effective therapeutic strategy for secondary prevention. In this review, we highlighted the roles of several inflammatory pathways in rupture and erosion, two major processes through which established plaques lead to adverse cardiovascular events. In the past 15 years, numerous clinical trials have tested the therapeutic potential of targeting these pathways, including neutralizing inflammatory cytokines and blocking signaling transduction of the inflammatory pathways. Only colchicine was approved for clinical use in patients with CAD. This is primarily due to the multifaceted roles of inflammatory pathways in disease progression. Commonly used pre-clinical models provided robust information for the onset of early disease but limited understanding of the inflammatory network in established plaques. This review will summarize lessons learned from successful and failed clinical trials to advocate for assessing inflammation in established plaques before designing therapeutics for secondary prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada.
- Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada.
ORCID-Profile: Ying Wang
Förderung
- Heart and Stroke Foundation of Canada
- Mitacs Accelerate Award
- Michael Smith Health Research British Columbia
Zitieren
APA
Cheng, W. H., & Wang, Y. (2025). Inflammatory Pathways in Coronary Artery Disease: Which Ones to Target for Secondary Prevention?. Cells. https://doi.org/10.3390/cells14030153
Vancouver
Cheng WH, Wang Y. Inflammatory Pathways in Coronary Artery Disease: Which Ones to Target for Secondary Prevention?. Cells. 2025. doi:10.3390/cells14030153
BibTeX
@article{Cheng2025,
author = {Cheng, Wan-Hei and Wang, Ying},
title = {Inflammatory Pathways in Coronary Artery Disease: Which Ones to Target for Secondary Prevention?},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14030153}
}
EUVIMED